Finance

Lists
Why is BBNX down 2.72%?
Dive Deeper
BBNX:NASDAQ
Beta Bionics Inc
$22.19
-2.72%
(-0.62) 1D
$22.19
0.00% (0.00)
After hours
Closed: Sep 23, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BBNX...
Open
$23.00
High
$23.48
Low
$21.88
Mkt. cap
1.17B
Avg. vol.
1.33M
Volume
1.40M
52-wk high
$32.71
52-wk low
$8.80
EPS
-$1.65
Shares outstanding
52.64M
No. of employees
422
Open
$23.00
High
$23.48
Low
$21.88
Mkt. cap
1.17B
Avg. vol.
1.33M
Volume
1.40M
52-wk high
$32.71
52-wk low
$8.80
EPS
-$1.65
Shares outstanding
52.64M
No. of employees
422
News stories
From web sources and news partners
About Beta Bionics Inc
CEO-
Employees422
Founded2015
HeadquartersIrvine, California, United States
SectorMedical device
Websitebetabionics.com
Analyst ratings
Based on 13 analysts giving stock ratings to BBNX in the past 3 months
Buy
Buy
9
Hold
4
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for BBNX in the last 3 months.
Highest
Current $22.19
$30.40 (+37.00%)
Average
$22.78 (+2.66%)
Lowest
$16.00 (-27.90%)
Analyst
Recommendation
Action
Price target
Projected
Date
Larry Biegelsen
Wells Fargo
Buy
Initiated
$28.00
+26.2%
09/23/2026
Frank Takkinen
Lake Street
Buy
Reiterated
$25.00
+12.7%
09/22/2026
Mike Kratky
Leerink Partners
Buy
Reiterated
$27.00
+21.7%
09/17/2026
Jonathan Block
Stifel Nicolaus
Buy
Maintained
$22.00
-0.9%
09/15/2026
Jeff Johnson
Robert W. Baird
Hold
Maintained
$16.00
-27.9%
09/15/2026
Patrick Wood
UBS
Buy
Maintained
$25.00
+12.7%
09/15/2026
Travis Steed
Bank of America Securities
Hold
Reiterated
$20.00
-9.9%
09/14/2026
Mathew Blackman
TD Cowen
Hold
Maintained
$18.00
-18.9%
09/14/2026
Steven Lichtman
William Blair
Hold
Maintained
-
-
09/14/2026
Richard Newitter
Truist Financial
Buy
Reiterated
$23.00
+3.7%
09/15/2026
Jeffrey Cohen
Ladenburg Thalmann & Co.
Buy
Reiterated
$30.40
+37%
07/30/2026
Matthew O'Brien
Piper Sandler
Buy
Reiterated
$20.00
-9.9%
07/30/2026
Danielle Antalffy
UBS
Buy
Initiated
$22.00
-0.9%
07/28/2026
David Roman
Goldman Sachs
Buy
Reiterated
$19.00
-14.4%
07/15/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
27.25M
32.12M
27.63M
32.01M
Cost of goods sold
12.13M
13.18M
11.19M
13.11M
Cost of revenue
12.13M
13.18M
11.19M
13.11M
Research and development expenses
8.20M
10.13M
10.36M
10.24M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
23.97M
24.94M
30.35M
34.24M
Operating expense
32.16M
35.07M
40.71M
44.48M
Total operating expenses
44.30M
48.24M
51.90M
57.59M
Operating income
-17.04M
-16.12M
-24.27M
-25.58M
Other non operating income
1.00K
-
-
-2.00K
EBT including unusual items
-14.21M
-13.47M
-21.90M
-23.40M
EBT excluding unusual items
-14.21M
-13.47M
-21.90M
-23.40M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-14.21M
-13.47M
-21.90M
-23.40M
Net profit margin
-52.14%
-41.92%
-79.25%
-73.10%
Earnings per share
-0.33
-0.19
-0.36
-0.36
Interest and investment income
2.83M
2.66M
2.38M
2.18M
Interest expense
-
-
-
-
Net interest expenses
2.83M
2.66M
2.38M
2.18M
Depreciation and amortization charges
-
-
-
-
EBITDA
-16.66M
-15.59M
-23.69M
-24.87M
Gain or loss from assets sale
-
31.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps